Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kuros Bioscience Ltd (OP: CSBTF )

27.70 UNCHANGED
Streaming Delayed Price Updated: 10:11 AM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 27.70
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 27.70
Today's Range 27.70 - 27.70
52wk Range 3.850 - 36.10
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kuros Biosciences Expands into Extremities Markets
Via ACCESSWIRE
Kuros Reports 149% Increase in Direct MagnetOs Sales and Exceeds Cash Flow Breakeven in the First Nine Months of 2024
Via ACCESSWIRE

Performance

YTD
+478.29%
+478.29%
1 Month
-8.55%
-8.55%
3 Month
+38.50%
+38.50%
6 Month
+175.62%
+175.62%
1 Year
+422.64%
+422.64%

More News

Read More
Kuros Biosciences Reports First Half of 2024 Results
Via ACCESSWIRE
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
Via ACCESSWIRE
Kuros Reports Corporate Highlights as of Q1 2024 Including Increase in Direct MagnetOsTM Sales
Via ACCESSWIRE
Annual General Meeting of Kuros Biosciences Approves All Resolutions
Via ACCESSWIRE
Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023
Via ACCESSWIRE
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
Via ACCESSWIRE
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
Via ACCESSWIRE
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
Via ACCESSWIRE
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
Via ACCESSWIRE
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
Via ACCESSWIRE
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
Via ACCESSWIRE
Kuros Reports a 150% Increase in Direct MagnetOs Sales in the First Nine Months of 2023 and Announces Changes Within the Executive Management
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.